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Abstract
We present a case to demonstrate the feasibility of pulmonary artery monitoring with the CardioMEMS sensor for the preoperative opti-
mization of patients with end-stage heart failure undergoing LVAD surgery. Additionally, we demonstrate the feasibility of combining two
state-of-the-art techniques by integrating haemodynamic feedback from CardioMEMS and static pump settings of an LVAD. CardioMEMS
aids in the remote monitoring of LVAD patients with the potential of identifying complications, pump dysfunction or filling status
alterations.
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INTRODUCTION
Currently, CardioMEMS is used for the remote monitoring of
patients with chronic heart failure (HF) [1, 2], and has been
applied, to a certain extent, in patients from the CHAMPION trial
who required LVAD implantation or in patients post-LVAD im-
plantation [3, 4]. However, we hypothesize that haemodynamic
data from the CardioMEMS system can be used to optimize pa-
tient haemodynamics pre-LVAD implantation, in addition to
echocardiographic and clinical parameters. We believe that low-
ering pulmonary artery pressure (PAP), ideally aiming for a mean
PAP (mPAP) <25mmHg, which is an indication of optimal decon-
gestion of the right ventricle (RV), is the best way to proceed to-
wards surgery.
Figure 1: (A) Daily PAPs, prior and post-LVAD implantation. (B) PAP reading shortly after CardioMEMS implantation, showing a clear notch, indicating severe mitral
valve insufficiency. (C) PAPs, after optimization; PAPs are within the target range, and the notch has disappeared. (D) PAPs, after LVAD implantation, showing that the
CardioMEMS provides a good quality signal after LVAD implantation. LVAD: left ventricular assist device; PA: pulmonary artery; PAP: pulmonary artery pressure.
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PATIENT DEMONSTRATION
We present a 62-year-old female, with a history of severe HF due
to familial, dilated, non-ischaemic cardiomyopathy and implant-
ation of a biventricular implantable cardioverter-defibrillator
(ICD). Patient was admitted for progressive end-stage HF with
elevated filling pressures, despite optimal medical treatment. An
initial echocardiogram showed an ejection fraction of 20%, se-
vere mitral valve insufficiency (MI), a tricuspid valve regurgitation
gradient of 31 mmHg and a dilated vena cava.
At admission, the patient was in INTERMACS class 2, and was
initially optimized using inotropic (enoximone) and intravenous
diuretics in order to achieve an euvolemic state. This was, how-
ever, hindered by renal insufficiency and inotrope-induced non-
sustained ventricular tachycardia. Based on physical and labora-
tory findings (pulse 60/min, blood pressure 90/50 mmHg, central
venous pressure (CVP) not elevated, signs of oedema absent, N-
terminal prohormone of brain natriuretic peptide (NT-proBNP)
was 470 pmol/L (at administration 1182 pmol/L)), patient was
deemed to be in an optimal state, was screened and accepted for
LVAD implantation as bridge-to-candidacy (as an adenocarcin-
oma polyp was recently removed from her colon), with an
EUROMACS-RHF risk-score of 4.
At this moment, the implanted CardioMEMS system showed
an elevated mPAP (35 mmHg), and a notch, indicating severe MI
(Fig. 1B). An echocardiogram showed severe, eccentric MI. mPAP
(Fig. 1A) was monitored to optimize the patient’s fluid state by
titrating diuretics in order to manage the combination of low-
output HF and renal insufficiency. mPAP was optimized to
19 mmHg (Fig. 1C), and on echocardiogram, the MI appeared to
be reduced to mild-to-moderate. Inotropic support was discon-
tinued, and the INTERMACS class improved to 4, reducing the
EUROMACS-RHF risk-score to 0 preoperatively.
LVAD implantation was successful performed (Fig. 2) 17 days
after CardioMEMS implantation. Postoperatively, haemodynamic
support was quickly phased out, without signs of RV failure. No
interference between the LVAD, hospital equipment and the
CardioMEMS system was observed. PAP was elevated as a result
of transfusions after implantation, and continued to rise as a sign
of congestion. The PAPs were used to optimize HF therapy (up-
titrating diuretics, mineralocorticoid receptor antagonists (MRA)
and renin-angiotensin-system (RAS)-blockers), resulting in a nor-
malization of the PAPs (Fig. 1D), and MI reduced to mild on
echocardiography. The patient remained stable without compli-
cations and was discharged on LVAD support in good clinical
condition.
DISCUSSION
The CardioMEMS device provides haemodynamic information
on a daily basis, which can be used by the treating clinician for
patient management. The use of this additional mode of haemo-
dynamic feedback will change the way clinicians work. Weekly
monitoring of the haemodynamic parameters allows for timely
reaction on haemodynamic changes and medication to be
adjusted accordingly, providing truly individualized therapy [2].
CardioMEMS is a very safe system, with only 1% of patients
developing device-related complications, and the most common
complication is bleeding at the puncture site after implantation,
which is easily managed [1].
In pre-LVAD management, clinical signs, laboratory results and
echocardiography are currently used to guide pre-LVAD opti-
mization. However, data describing the accuracy of these techni-
ques are lacking. Additional daily haemodynamic information is
very important to achieving true pre-LVAD optimization, as has
been shown in our case. Thus, unloading the RV and kidney could
potentially reduce the preoperative risk for RV and kidney failure.
Currently, post-implantation monitoring is limited to pump-
controller defined parameters, which display fixed number of
rotations, calculated pump flow and pulse index. Adding haemo-
dynamic changes measured with the CardioMEMS could lead to
earlier detection of complications, such as major bleeding, tam-
ponade, RV-failure, decompensation or arrhythmia. Earlier detec-
tion facilitates earlier treatment, potentially improving outcome.
Currently, this new technology is only used in clinical trials.
However, the combination of CardioMEMS and LVAD could en-
able telemonitoring of patients who have undergone LVAD
implantation.
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Figure 2: Chest X-ray, showing the HeartMate3, CardioMEMS and biventricular
ICD. ICD: implantable cardioverter-defibrillator.
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